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Abstract
Background: Brain-derived ectonucleoside triphosphate diphosphohydrolases (NTPDases) have been
known as plasma membrane-incorporated enzymes with their ATP-hydrolyzing domain outside of the cell.
As such, these enzymes are thought to regulate purinergic intercellular signaling by hydrolyzing ATP to
ADP-AMP, thus regulating the availability of specific ligands for various P2X and P2Y purinergic receptors.
The role of NTPDases in the central nervous system is little understood. The two major reasons are the
insufficient knowledge of the precise localization of these enzymes in neural structures, and the lack of
specific inhibitors for the various NTPDases. To fill these gaps, we recently studied the presence of
neuron-specific NTPDase3 in the mitochondria of hypothalamic excitatory neurons by morphological and
functional methods. Results from those studies suggested that intramitochondrial regulation of ATP levels
may play a permissive role in the neural regulation of physiological functions by tuning the level of ATP-
carried energy that is needed for neuronal functions, such as neurotransmission and/or intracellular
signaling.
Presentation of the hypothesis: In the lack of highly specific inhibitors, the determination of the
precise function and role of NTPDases is hardly feasable. Yet, here we attempt to find an approach to
investigate a possible role for hypothalamic NTPDase3 in the initiation of the midcycle luteinizing hormone
(LH) surge, as such a biological role was implied by our recent findings. Here we hypothesize that
NTPDase-activity in neurons of the AN may play a permissive role in the regulation of the estrogen-
induced pituitary LH-surge.
Testing the hypothesis: We propose to test our hypothesis on ovariectomized rats, by stereotaxically
injecting 17beta-estradiol and/or an NTPDase-inhibitor into the arcuate nucleus and determine the
consequential levels of blood LH, mitochondrial respiration rates from arcuate nucleus synaptosomal
preparations, NTPDase3-expression from arcuate nucleus tissue samples, all compared to sham and intact
controls.
Implications of the hypothesis: Results from these studies may lead to the conclusion that estrogen
may modulate the activity of mitochondrial, synapse-linked NTPDase3, and may show a correlation
between mitochondrial NTPDase3-activity and the regulation of LH-release by estrogen.
Published: 16 June 2009
Reproductive Biology and Endocrinology 2009, 7:63 doi:10.1186/1477-7827-7-63
Received: 25 February 2009
Accepted: 16 June 2009
This article is available from: http://www.rbej.com/content/7/1/63
© 2009 Zsarnovszky et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2009, 7:63 http://www.rbej.com/content/7/1/63Background
NTPDases (also known as ectonucleotidases or ecto-apy-
rases) have been described as an 8-member family of
nucleotidase enzymes. Most NTPDases are integral mem-
brane proteins: NTPDase1 [1], NTPDase2 [2], NTPDase3
[3,4] and NTPDase8 [5] reside in the plasma membrane
with their active site outside of the cell. These cell surface
enzymes hydrolyze extracellular nucleotides, thus regulat-
ing the availability of specific ligands for P2X and P2Y
purinergic receptors. In certain tissues, nucleoside mono-
phosphates are further hydrolyzed by 5'-ectonucleotidase
to adenosine that activates P1 adenosine receptors.
NTPDase4–8 have not been detected in the brain.
Of the NTPDases, types 1, 2 and 3 have been identified
and studied in the brain. NTPDase1 was identified in neu-
rons, glia and endothelial cells of the rat brain [6,7],
whereas NTPDase2 was detected mostly in the germinal
zones of the rat CNS; Type-B cells also expressed
NTPDase2 [8]. NTPDase3 mRNA was first identified in
the brain by Chadwick and Frischauf [4], and we recently
determined the tissue distribution of this enzyme in the
rat brain [9]. In the latter study, we suggested that
NTPDase3 is neuron-specific, with the enzyme being
present in neuronal perikarya and neuronal processes.
NTPDase3-immunoreactive (NTPDase3-IR) perikarya
were only observed in the arcuate nucleus (AN) and the
lateral hypothalamic nucleus (LHN). In our most recent
work we further characterized the subcellular localization
of NTPDase3 in the hypothalamus [10]. As part of the lat-
ter correlated light- and electron microscopic examina-
tions, we identified NTPDase3-IR in the mitochondrial
matrix or closely linked to the inner mitochondrial mem-
brane of hypothalamic neurons. Additionally, immuno-
histochemical and electron microscopic studies strongly
implied that hypothalamic NTPDase3-IR may only be
found in excitatory neurons. Those morphological results
demonstrating NTPDase3 in the neuronal mitochondrial
matrix were confirmed by functional studies where synap-
tosomal fractions from hypothalamic tissue homogenates
were subjected to mitochondrial respiration measure-
ments. We found that decrease of NTPDase-activity by the
use of an NTPDase- (including NTPDase3) inhibitor
resulted in significantly decreased ADP-dependent state 3
mitochondrial respiration rate and total mitochondrial
respiratory capacity. Since neuronal activity, especially
neurotransmission is highly energy dependent [11], it was
reasonable to assume that hypothalamic neuronal activ-
ity, especially that of excitatory neurons, may be depend-
ent on the activity of mitochondrial NTPDase3 due to the
ATPase activity of this enzyme.
The neuroendocrine hypothalamus is the target of a
number of peripheral hormones that function as signals
for the feedback-based regulation of various homeostatic
systems. Estrogen, for example, targets numerous hypoth-
alamic neurons, including those of the arcuate nucleus, to
regulate the GnRH- and consequential pituitary LH-surge.
We and others have previously demonstrated that in non-
human primates, as well as in rats, considerable synaptic
events take place in the neuroendocrine hypothalamus,
termed the „estrogen-induced hypothalamic synaptic
plasticity“ (EISP). EISP is marked by a well-defined pat-
tern of synaptic reorganization of both excitatory (mainly
during the positive gonadotrophin feedback) and subse-
quently, inhibitory interneuronal contacts [12,13]. Since
the AN (besides the LHN) is one of the hypothalamic
structures hosting NTPDase3-IR neuronal perikarya, we
wanted to know whether varying estrogen levels influence
the hypothalamic expression level of NTPDase3. There-
fore, we carried out studies [10] to investigate the effects
of the absence or presence of estrogen on medial- and lat-
eral hypothalamic NTPDase3-levels. Results from Western
blot analyses showed a time- and estrogen-dependent pat-
tern of changes in NTPDase3-expression levels in both the
medial and lateral sides of the sampled hypothalami,
interestingly however, the temporal pattern of changes in
the medial and lateral sides differed. Specifically, in sam-
ples including the LHN, NTPDase3 levels increased signif-
icantly 4–12 hrs after a single subcutaneous injection of
estrogen, and gradually returned to nearly control (ovx)
levels by 16–26 hrs after estrogen-treatment. In contrast,
temporal changes in medial hypothalamic samples
including the AN showed an initial increase in NTPDase3-
expression between 6–10 hrs after estrogen-treatment, fol-
lowed by a sharp decrease to control levels, and again fol-
lowed by a second rise between 22–26 hrs after estrogen-
treatment. Thus, in the lateral hypothalamus a single-,
whereas in the medial hypothalamus a double-peaked
curve was determined, suggesting that NTPDase3-expres-
sion in the hypothalamus is regulated by estrogen, how-
ever, the role of these enzymes (including NTPDase3) in
the two hypothalamic regions might be different. Based
on the aforementioned double-peaked curve detected in
medial hypothalamic samples, it was reasonable to
assume that the temporal changes in medial hypotha-
lamic NTPDase3-expression could correspond to the initi-
ation of the two successive phases of the GnRH-regulating
feedback mechanism, i.e., the estrogen-induced positive-
and successive negative (reciprocal) feedbacks. Our ongo-
ing pilot experiments also show that 10 hours after estro-
gen-treatment, when hypothalamic NTPDase3 levels are
high, inhibition of NTPDases in synaptosomes from
medial hypothalamic samples results in a more robust fall
in oxygen consumption during state 3 mitochondrial res-
piration, suggesting that estrogen-treatment increased
NTPDase-activity in synaptosomal mitochondria. It is
important to note that previous studies carried out on syn-
aptosomes from several brain regions suggested that the
ecto-ATPase activity detectable under such experimentalPage 2 of 5
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than any of the two other (NTPDase1 or NTPDase2) NTP-
Dases present in the CNS [14,15]. Additionally, in a
review summary by Langer et al. [16] of the present
knowledge of the distribution of different NTPDases in
the brain, the authors arrived to the conclusion that in the
lack of considerable amounts of other NTPDases, much of
the ATPase activity in the hypothalamus is attributable to
NTPDase3. These observations argue for a role of
NTPDase3 in the tuning of neuronal ATP-availability in
the hypothalamus and, consequentially, for a permissive
role of NTPDase3 in the initiation of EISP and in the reg-
ulation of the pituitary LH-release.
Presentation of the hypothesis
Our initial results described above lead us to the hypoth-
esis that NTPDase-activity in neurons of the AN may play
a permissive role in the regulation of the estrogen-induced
pituitary LH-surge.
Testing the hypothesis
At least five healthy, normal cycling female rats per each
parameter examined (see below) will be used for the
study. Animals will be ovariectomized (ovx) 7 days prior
to further experimentation. Seven days after ovariectomy,
animals will receive stereotaxic intracerebral (i.c) injec-
tions into the arcuate nucleus, using the stereotaxic coor-
dinates provided by Paxinos and Watson [17], as follows:
Group 1 will receive 17beta-estradiol (E2) 20 minutes
after initial injection of saline; Group 2 will receive E2 20
minutes after initial i.c. injection of suramin (NTPDase-
inhibitor); Group 3 will receive two consecutive injections
of physiological saline (sham control) with a timing pre-
sented above. An additional group of animals (Group 4)
not subjected to i.c. injections will be investigated as
described below. Animals will be sacrificed 2-6-10-18 and
26 hours after the i.c. injections. Blood samples will be
drawn from each individual and plasma LH will be deter-
mined. Brains will be quickly removed and tissue samples
containing the arcuate nucleus will be obtained by punch
sampling biopsy technique as described by Palkovits and
Brownstein [18]. Tissue samples will be homogenized and
protein concentrations quickly determined. Based on
sample protein concentrations, aliquotes will be prepared
from tissue homogenates for further determination of
NTPDase3-levels by Western blot analysis.
Mitochondrial oxygen consumption (mitochondrial res-
piration rates, especially ADP-dependent state 3 respira-
tion and total mitochondrial respiratory capacity) will be
determined from synaptosomal preparations of tissue
aliquotes without further inhibition (suramin) of the
sample (i.e., the left-sided medial hypothalamus), or with
further suramin-treatment of the contralateral (i.e., the
right-sided) sample. Please note that the initial, i.c. injec-
tion of suramin is necessary to test the effect of NTPDase-
inhibition on plasma LH levels (mitochondrial respira-
tion measurement results of left-sided samples should be
viewed in light of the LH concentration measured), while
further in loco treatment of the right-sided samples allows
the determination and therefore the better comparison of
NTPDase activities among group-members. It should be
noted that since no selective NTPDase3-inhibitor is avail-
able to-date, the proposed experiments will also be per-
formed using alternative inhibitors that are preferably less
potent purinoceptor antagonists. It is also necessary that
the results from the proposed experiments be confirmed
once a specific inhibitor, that does not affect purinergic
receptors but is highly specific for NTPDase3, becomes
available.
The experimental design is summarized in Figure 1.
Implications of the hypothesis
With the proposed hypothesis it is our goal to prompt fur-
ther studies that investigate the relationship between the
NTPDase-dependent energetic status of cells and their rel-
evant biological functions.
NTPDase3 has been previously found in the mediobasal
hypothalamus [9]. Since one of the major roles of the AN
is to regulate the GnRH and consequential LH release, the
presence of NTPDase3 in AN neurons implied a role for
this enzyme in the aforementioned hypothalamic regula-
tory mechanism. Since, however, NTPDase3 has been
generally known as a trans-membrane enzyme that hydro-
lyzes ATP to modulate the availability of specific ligands
for various purinergic receptors, one would speculate that
such biological role, if exists, for NTPDase3 is achieved by
the influence of NTPDase3 enzymatic activity on puriner-
gic neurotransmission. This idea would be supported by a
number of previous observations, including and involv-
ing the function of various purinoceptors, [19] in the
mediobasal hypothalamus. It is conflicting, however, that
no evidence surfaced to-date that would indicate a role for
purinoceptors in the AN in the regulation of GnRH/LH
release. Therefore, based on our previous findings [10], it
is reasonable to assume that NTPDase3 may influence
GnRH/LH release through intracellular enzymatic activ-
ity, one of which may involve the mitochondrial regula-
tion of ATP amounts. To-date, NTPDase3 has been found
in several organs including the CNS, pancreas, cardiomy-
ocytes, lung respiratory epithelium and the Leidig cells of
the testis; and in each case, NTPDase3-function was con-
sidered as an extracellular ectonucleotidase activity func-
tionally linked to purinergic signaling. In other words, the
role of NTPDase3 in the listed organ- or tissue specific
functions was, therefore, discussed in the context of a
membrane-bound ATPase-ADPase enzyme. Unfortu-
nately, those studies failed to investigate and determinePage 3 of 5
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including electron microscopy or subcellular fractiona-
tion. Therefore, the idea of subcellular, compartment-
linked NTPDase functions in the CNS has not emerged.
While the function of NTPDase3 has been mostly tested
by receptor antagonists, increasing efforts have been made
to find selective blockers for the enzyme itself. Despite of
those efforts, a fully specific inhibitor has not yet been
found. Today, the lack of such specific blockers is a con-
siderable drawback of NTPDase-research. Yet, some of the
purin receptor antagonists are also capable of inhibiting
NTPDase enzyme activity. One such inhibitor for NTP-
Dases is the polyoxometalate suramine. Although
suramine (and its analogues) cannot be considered for
selective inhibition of receptors or NTPDase-activity, it
can be used in some subcellular fractions of biological
samples, such as synaptosomal fractions isolated from
various sources. As cited above, few studies investigated
the ATPase activity of brain NTPDases in synaptosomal
fractions, however, none of those examined a functional
link between mitochondrial respiration and NTPDase
activity. We, in our most recent study, demonstrated that
inhibition of NTPDase activity in synaptosomal fractions
decreased ADP-dependent state 3 mitochondrial respira-
tion, and that the hypothalamic NTPDase3 expression
and the mitochondrial state 3 respiration rates are
dependent on the actual estrogenic background [10].
These results suggest the possibility that estrogen may set
the amount of mitochondrial ATP near synapses and
thereby influence synaptic transmission by modulating its
ATP-supply.
Expected results
As described in the hypothesis, we expect that inhibition
of NTPDases in the AN would prevent the estrogen-
induced pituitary LH release. Inhibition of AN NTPDase-
activity may affect changes in intercellular purinergic sig-
naling and may also influence intracellular energy states
by the hydrolytic activity of mitochondrial NTPDase.
Numerous studies reported that extracellular ATP
increases the activity level of GnRH neurons and the pitu-
itary gonadotrops [20-23]. On this line one would specu-
late that the inhibition of extracellular ATP hydrolysis by
NTPDases would result in longer-lasting elevated extracel-
lular ATP levels leading to the facilitation of the pituitary
LH-release. However, to the best of our knowledge, no evi-
dence exists that would suggest a role for AN purinocep-
tors in the regulation of GnRH/LH release. Therefore, by
the local, intra-AN application of suramin, the effects of
the inhibitor on neurons outside of the AN (such as the
medial preoptic area and the anterior pituitary) could be
discounted, and the effects could be attributed to the
intracellular inhibition of NTPDases, NTPDase3 in partic-
ular.
The proposed, yet to be tested mechanism would involve
the inhibition of mitochondrial NTPDase-activity in
hypothalamic neurons, thereby leading to a momentary
increase in mitochondrial ATP levels, but a subsequent
silencing of mitochondrial respiration (as suggested by
the decrease of state 3 mitochondrial respiration rates
after NTPDase-inhibition); As a result, a halt in mitochon-
drial ATP production would occur. In this case, NTPDase-
containing nerve terminals would not have sufficient
Experimental design for testing the proposed hypothesisFigu e 1
Experimental design for testing the proposed 
hypothesis. Animals will be ovariectomized (ovx) 7 days 
prior to further experimentation. Seven days after ovariec-
tomy, animals will receive intracerebral (i.c.) stereotaxic 
injections into the arcuate nucleus as follows: Group 1 will 
receive 17beta-estradiol (E2) 20 minutes after initial injection 
of saline; Group 2 will receive E2 20 minutes after initial i.c. 
injection of suramin (NTPDase-inhibitor); Group 3 will 
receive two consecutive injections of physiological saline 
(sham control) with a timing presented above. An additional 
group of animals (Group 4) not subjected to i.c. injections 
will be investigated. Animals will be sacrificed 2-6-10-18 and 
26 hours after the i.c. injections. Blood samples will be drawn 
from each individual and plasma LH will be determined. 
Brains will be quickly removed and the medial part of the 
hypothalami will be isolated. Tissue samples from left and 
right sides will be separately handled. Tissue samples will be 
homogenized and protein concentrations quickly deter-
mined. Based on sample protein concentrations, aliquotes 
will be prepared from tissue homogenates for further deter-
mination of NTPDase3-levels by Western blot analysis. Mito-
chondrial oxygen consumption (mitochondrial respiration 
rates, especially ADP-dependent state 3 respiration and total 
mitochondrial respiratory capacity) will be determined from 
synaptosomal preparations of tissue aliquotes without fur-
ther inhibition (suramin) of the sample (i.e., the left-sided 
medial hypothalamus), or with further suramin-pretreatment 
of the contralateral (i.e., the right-sided) sample.Page 4 of 5
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amounts of ATP to fuel neurotransmission, therefore, the
highly energy-demanding EISP could not be initiated,
thus preventing pituitary LH-release.
In any case, testing the possible influence of NTPDase-
inhibition on pituitary LH-release will bring us closer to
understand the relationship between the considerably
versatile neuronal ATP functions and the hypothalamic
regulation of pituitary LH-release.
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